Back to results
US 2017/0000909 A1Published application
Enzyme directed assembly of particle theranostics
AssigneeThe Regents of the University of California
InventorsNathan C. Gianneschi, Michael Hahn, Robert Mattrey
Life of this patent
Estimating the term…
Abstract
Provided herein, inter alia, are compositions, methods of detecting a diseased tissue in a subject, and methods of treating a subject having cancer.
Claims31
A compound comprising:
- a polymer of monomers forming a first portion of monomers and a second portion of monomers, said first portion of monomers each conjugated to a hydrophobic moiety through a first linker, and said second portion of monomers each conjugated to a hydrophilic moiety through an enzyme cleavable moiety;
- wherein said first portion of monomers or second portion of monomers further comprise a visualizable label, a therapeutic agent, or a targeting moiety.
A method of detecting diseased tissue in a subject comprising:
- (a) administering a compound to the subject;
- wherein the compound comprises a hydrophilic polymer with an enzyme cleavable moiety and a visualizable label;
- wherein the enzyme cleavable moiety is cleaved by an enzyme present in a diseased tissue, and
- wherein cleavage of the enzyme cleavable moiety in the compound causes the compound to self-assemble into an amphiphilic polymer aggregate comprising an amphiphilic polymer and the visualizable label;
- and
- (b) determining the presence or absence of amphiphilic polymer aggregate in a tissue in the subject, wherein the presence of amphiphilic polymer aggregate in the tissue indicates that the tissue is diseased;
- and
- (c) detecting diseased tissue in the subject where amphiphilic polymer aggregate is present.
5 more elements
(canceled)
(canceled)
(canceled)
A method of treating a subject having cancer, the method comprising:
- (a) administering a compound to the subject;
- wherein the compound comprises a hydrophilic polymer with an enzyme cleavable moiety, a therapeutic agent, and a targeting moiety,
- wherein the enzyme cleavable moiety is cleaved by an enzyme present in a diseased tissue, and;
- wherein cleavage of the enzyme cleavable moiety in the compound causes the compound to self-assemble into an amphiphilic polymer aggregate acting to target the material to the tissue, and where the aggregate comprises polymeric material and the therapeutic agent;
- (b) allowing a targeting moiety to localize the compound to a targeted tissue in the subject as directed by the targeting moiety in addition to enzymatically-driven aggregation targeting;
- and
- (c) treating a subject with cancer in the subject by exposing the targeted tissue to the amphiphilic polymer aggregate containing a therapeutic agent.
4 more elements
(canceled)
20-21. (canceled)
An enzymatically-generated, self-assembled amphiphilic polymer aggregate comprising:
- an amphiphilic polymer comprising a hydrophilic cryptic-amphiphile associated with a polypeptide cleaved by a matrix metalloproteinase, and a visualizable label.
An enzymatically-generated self-assembled amphiphilic polymer aggregate comprising:
- an amphiphilic polymer comprising a hydrophilic cryptic-amphiphile associated with a nucleic acid structure cleaved by an enzyme, and a visualizable label.
27-28. (canceled)
Dependencies are inferred from the claim text.